The market taxonomy for Dengue Fever Testing by type distinguishes four technology families: NS1 antigen assays, IgM/IgG ELISA, reverse‑transcription polymerase chain reaction (RT‑PCR), and rapid diagnostic tests (RDTs). NS1 antigen assays detect circulating viral protein within the first week of infection, enabling early case confirmation; they dominate the laboratory‑based segment because of high sensitivity and moderate cost, contributing roughly 40 % of test volume. IgM/IgG ELISA measures host antibody response, extending detection to later stages and supporting seroprevalence studies; its broader dynamic range secures about 30 % of market share. RT‑PCR, offers definitive viral RNA identification and quantification, essential for confirmatory testing and epidemiological typing, yet its higher instrument and reagent costs limit adoption to reference centers, representing near 20 % of revenue. RDTs, typically lateral‑flow immunochromatographic devices, provide point‑of‑care results within minutes, crucial for low‑resource settings; they account for the remaining 10 % of the market. Each type’s cost structure, turnaround time, and performance profile dictate its proportional contribution to overall market size.